| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Laboratorios Farmaceuticos Rovi S.A (MC: ROVI)
ROVI Technical Analysis
4
| As on 13th Mar 2025 ROVI STOCK Price closed @ 52.25 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 71.72 & Sell for SHORT-TERM with Stoploss of 52.50 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ROVISTOCK Price
| Open | 52.40 | Change | Price | % |
| High | 52.85 | 1 Day | 0.05 | 0.10 |
| Low | 51.90 | 1 Week | -1.65 | -3.06 |
| Close | 52.25 | 1 Month | -13.25 | -20.23 |
| Volume | 82805 | 1 Year | 1.65 | 3.26 |
| 52 Week High 91.50 | 52 Week Low 47.62 | ||||
MC Spain Most Active Stocks
| IAG | 3.29 | -0.60% |
| UBS | 0.00 | % |
| SAN | 6.01 | 0.17% |
| AMP | 0.14 | 7.69% |
| TEF | 4.35 | 2.84% |
| SAB | 2.65 | -1.12% |
| BBVA | 12.77 | -0.85% |
| CABK | 6.96 | 0.00% |
| BKY | 0.26 | 4.00% |
| IBE | 13.90 | 1.02% |
MC Spain Top Gainers Stocks
MC Spain Top Losers Stocks
| ROVI Daily Charts |
ROVI Intraday Charts |
Whats New @ Bazaartrend |
ROVI Free Analysis |
|
|
ROVI Important Levels Intraday
| RESISTANCE | 54.08 |
| RESISTANCE | 53.49 |
| RESISTANCE | 53.13 |
| RESISTANCE | 52.77 |
| SUPPORT | 51.73 |
| SUPPORT | 51.37 |
| SUPPORT | 51.01 |
| SUPPORT | 50.42 |
ROVI Forecast March 2025
| 4th UP Forecast | 71.08 |
| 3rd UP Forecast | 65.04 |
| 2nd UP Forecast | 61.31 |
| 1st UP Forecast | 57.57 |
| 1st DOWN Forecast | 46.93 |
| 2nd DOWN Forecast | 43.19 |
| 3rd DOWN Forecast | 39.46 |
| 4th DOWN Forecast | 33.42 |
ROVI Weekly Forecast
| 4th UP Forecast | 61.48 |
| 3rd UP Forecast | 58.52 |
| 2nd UP Forecast | 56.69 |
| 1st UP Forecast | 54.86 |
| 1st DOWN Forecast | 49.64 |
| 2nd DOWN Forecast | 47.81 |
| 3rd DOWN Forecast | 45.98 |
| 4th DOWN Forecast | 43.02 |
ROVI Forecast2025
| 4th UP Forecast | 144.78 |
| 3rd UP Forecast | 115.11 |
| 2nd UP Forecast | 96.76 |
| 1st UP Forecast | 78.42 |
| 1st DOWN Forecast | 26.08 |
| 2nd DOWN Forecast | 7.74 |
| 3rd DOWN Forecast | -10.61 |
| 4th DOWN Forecast | -40.28 |
Laboratorios Farmaceuticos Rovi S.A ( MC Spain Symbol : ROVI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ROVI Business Profile
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L. Address: Calle José Isbert, 2, Madrid, Spain, 28223
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service